Core Insights - Natera (NTRA) has launched Zenith genomics, a next-generation whole genome sequencing assay aimed at enhancing the detection and diagnosis of rare genetic diseases [2][8] - The technology was developed in partnership with MyOme, which specializes in clinical whole genome analysis [2][4] - Natera plans to utilize its extensive infrastructure, including electronic medical record integration and clinical support systems, to distribute Zenith genomics across the United States [3][6] Company Developments - The launch of Zenith genomics is expected to strengthen Natera's growth outlook by expanding its footprint in the rare disease diagnostics market, which is rapidly growing [6] - The assay aims to improve diagnostic clarity and accuracy for patients with suspected rare genetic disorders by utilizing advanced sequencing technologies [10][11] - Natera's current market capitalization stands at $26.62 billion [7] Market Context - Rare diseases affect approximately 30 million people in the United States, with many patients experiencing significant delays in diagnosis [13] - The economic burden of rare diseases in the U.S. was estimated at $997 billion in 2019, underscoring the need for improved diagnostic solutions [13] - The genetic testing market is projected to reach $27.32 billion by 2026, with a compound annual growth rate (CAGR) of 11.3% through 2035, driven by increasing incidences of genetic disorders and advancements in testing technologies [14]